29 August 2018
ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, successfully closed an equity financing round. The company raised CHF 5.2 mio. from existing investors.
VISCHER advised on all Swiss legal issues related to the transaction. The VISCHER team includes Mattias Staehelin (Partner, Corporate/M&A) and Moritz Jäggy (Managing Associate, Corporate/M&A).